The Enterprise Value as of November 2024 (TTM) for Immunovant, Inc. (IMVT) is 3.47B

According to Immunovant, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 3.47B. This represents a change of -15.95% compared to the average of 4.13B of the last 4 quarters.

Immunovant, Inc. (IMVT) Historical Enterprise Value (quarterly & annually)

How has IMVT Enterprise Value performed in the past?

The mean historical Enterprise Value of Immunovant, Inc. over the last ten years is 1.03B. The current 3.47B Enterprise Value has changed 33.62% with respect to the historical average. Over the past ten years (40 quarters), IMVT's Enterprise Value was at its highest in in the December 2023 quarter at 5.40B. The Enterprise Value was at its lowest in in the September 2018 quarter at 0.

Immunovant, Inc. (IMVT) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Immunovant, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Immunovant, Inc. (IMVT) Average Enterprise Value

How has IMVT Enterprise Value performed in the past?

The current Enterprise Value of Immunovant, Inc. (IMVT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Immunovant, Inc. (IMVT) Enterprise Value vs. Peers

How is IMVT’s Enterprise Value compared to its peers?

Immunovant, Inc.’s Enterprise Value is greater than Arbutus Biopharma Corporation (634.72M), greater than Arcutis Biotherapeutics, Inc. (1.26B), less than Legend Biotech Corporation (7.40B), greater than Protagonist Therapeutics, Inc. (2.65B), less than IVERIC bio, Inc. (0), less than Akero Therapeutics, Inc. (5.13B), greater than Madrigal Pharmaceuticals, Inc. (2.00B), less than Apellis Pharmaceuticals, Inc. (7.46B), less than 89bio, Inc. (3.90B), greater than Pliant Therapeutics, Inc. (940.63M), greater than Arcellx, Inc. (770.48M), less than Stoke Therapeutics, Inc. (4.79B), greater than Blueprint Medicines Corporation (457.69M), less than Amylyx Pharmaceuticals, Inc. (6.36B), greater than Karuna Therapeutics, Inc. (291.98M), less than Day One Biopharmaceuticals, Inc. (12.43B), greater than null (963.46M),

Build a custom stock screener for Immunovant, Inc. (IMVT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immunovant, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Immunovant, Inc. (IMVT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Immunovant, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.